Long-acting β-agonists: anti-inflammatory properties and synergy with corticosteroids in asthma

Purpose of review Contemporary asthma management calls for combination inhaled corticosteroid (ICS) and long-acting β-agonist (LABA) for patients with moderate to severe persistent asthma. This combination has consistently shown superior clinical efficacy compared with monotherapy with higher doses of ICS. It is unclear whether ICS and LABA act additively because of their complementary mechanisms of action, or whether they act synergistically based on possible favorable interactions between them. The purpose of this review is to summarize research findings on the anti-inflammatory activity of LABA published since October 2002 and to speculate on how these findings will affect future asthma management recommendations. Recent findings Combination ICS plus LABA consistently demonstrates superiority over ICS monotherapy in clinical outcomes such as pulmonary function, symptoms, and exacerbation rates, and is consistent with definitive data published before the review period. However, investigations into possible effects of LABA on inflammatory mediators are preliminary. Positive effects of LABA on some serum and bronchial inflammatory measures have been observed, but the clinical importance of these findings has not been established. Summary Current asthma treatment recommendations are based on clinical trials demonstrating improved clinical outcomes of combination ICS plus LABA over ICS alone. Whether LABA possesses clinically important benefits beyond bronchodilation remains to be established. Distinguishing anti-inflammatory activity of LABA will help define optimal long-term treatment regimens for asthma that not only improve pulmonary function, symptoms, and exacerbation rates but also protect against airway remodeling.

[1]  C. Jackson,et al.  Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma. , 2003, British journal of clinical pharmacology.

[2]  C. Jenkins,et al.  Formoterol (Foradil) and medium-high doses of inhaled corticosteroids are more effective than high doses of corticosteroids in moderate-to-severe asthma. , 2003, Pulmonary pharmacology & therapeutics.

[3]  D. Postma,et al.  The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma , 2003, European Respiratory Journal.

[4]  B. Lipworth,et al.  Effects of low dose fluticasone/salmeterol combination on surrogate inflammatory markers in moderate persistent asthma , 2003, Allergy.

[5]  B. Lipworth,et al.  Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma. , 2003, British journal of clinical pharmacology.

[6]  H. Boushey,et al.  Airway tissue mast cells in persistent asthma: predictor of treatment failure when patients discontinue inhaled corticosteroids. , 2003, Chest.

[7]  E. Walters,et al.  Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo , 2003, European Respiratory Journal.

[8]  J. Bousquet,et al.  Clinical and biological heterogeneity in children with moderate asthma. , 2003, American journal of respiratory and critical care medicine.

[9]  P. Ind,et al.  Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. , 2003, Respiratory medicine.

[10]  N. Thomson,et al.  Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. , 2003, Chest.

[11]  I. Naya,et al.  Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. , 2003, Respiratory medicine.

[12]  C. Jackson,et al.  Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients , 2003, European Journal of Clinical Pharmacology.

[13]  B. Lipworth,et al.  Dose response of inhaled corticosteroids on bronchial hyperresponsiveness: a meta-analysis. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[14]  C. Billington,et al.  Cyclic AMP-mobilizing agents and glucocorticoids modulate human smooth muscle cell migration. , 2003, American journal of respiratory cell and molecular biology.

[15]  L. Edwards,et al.  Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 μg administered twice daily , 2003 .

[16]  E. Bateman,et al.  Combination Therapy with Single Inhaler Budesonide/Formoterol Compared with High Dose of Fluticasone Propionate Alone in Patients with Moderate Persistent Asthma , 2003, American journal of respiratory medicine : drugs, devices, and other interventions.

[17]  S. Teelucksingh,et al.  Salmeterol decreases eosinophilic cationic protein and rescue medication in patients inhaling beclomethasone dipropionate: preliminary study in mild and moderate asthma in Trinidad, West Indies. , 2003, International journal of clinical pharmacology research.

[18]  T. Sandström,et al.  The effects of regular inhaled formoterol and budesonide on preformed Th-2 cytokines in mild asthmatics. , 2002, Respiratory medicine.

[19]  R. Dahl,et al.  Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study , 2002, European Respiratory Journal.

[20]  Malcolm W Johnson.  Effects of beta2-agonists on resident and infiltrating inflammatory cells. , 2002, The Journal of allergy and clinical immunology.

[21]  I. Pavord,et al.  Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial , 2002, The Lancet.

[22]  K. De Boeck,et al.  Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma , 2002, Pediatric pulmonology.

[23]  D. Price,et al.  Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose , 2002, Thorax.

[24]  P. Kuna,et al.  A randomized, double-blind trial of the effect of treatment with formoterol on clinical and inflammatory parameters of asthma in children. , 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[25]  P. Kuna,et al.  A randomized, double‐blind trial of the effect of glucocorticoid, antileukotriene and bβ‐agonist treatment on IL‐10 serum levels in children with asthma , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[26]  R. Brattsand,et al.  Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells. , 2001, The European respiratory journal.

[27]  D. Postma,et al.  Effects of budesonide and formoterol on eosinophil activation induced by human lung fibroblasts. , 2000, American journal of respiratory and critical care medicine.

[28]  S. Shrewsbury,et al.  Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA) , 2000, BMJ : British Medical Journal.

[29]  D. Postma,et al.  Budesonide and formoterol inhibit ICAM-1 and VCAM-1 expression of human lung fibroblasts. , 2000, The European respiratory journal.

[30]  M. Linden,et al.  Effects of β2-agonists and budesonide on interleukin-1β and leukotriene B4 secretion : Studies of human monocytes and alveolar macrophages , 1998 .

[31]  J. FitzGerald,et al.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. , 1998, The New England journal of medicine.

[32]  D. Postma,et al.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. , 1997, The New England journal of medicine.

[33]  D. McDonald,et al.  Inhibition of neutrophil and eosinophil adhesion to venules of rat trachea by beta 2-adrenergic agonist formoterol. , 1994, Journal of applied physiology.